BerandaTTNP • NASDAQ
add
Titan Pharmaceuticals, Inc. common stock
$5,73
Setelah Jam Perdagangan Normal:(1,74%)+0,100
$5,83
Tutup: 6 Sep, 19.34.51 GMT-4 · USD · NASDAQ · Pernyataan Penyangkalan
Tutup sebelumnya
$5,91
Rentang hari
$5,61 - $6,14
Rentang tahun
$4,24 - $14,80
Kapitalisasi pasar
5,24 jt USD
Volume Rata-Rata
924,53 rb
Rasio P/E
-
Hasil dividen
-
Bursa utama
NASDAQ
Dalam berita
Keuangan
Laporan Pendapatan
Pendapatan
Laba bersih
| (USD) | Jun 2024info | Perubahan Y/Y |
|---|---|---|
Pendapatan | — | — |
Biaya operasional | 2,07 jt | 68,76% |
Laba bersih | -2,09 jt | -31,97% |
Margin laba bersih | — | — |
Penghasilan per saham | — | — |
EBITDA | -2,07 jt | -33,70% |
Tarif pajak efektif | — | — |
Neraca
Total aset
Total liabilitas
| (USD) | Jun 2024info | Perubahan Y/Y |
|---|---|---|
Investasi tunai jangka pdk | 4,09 jt | 3.797,14% |
Total aset | 4,35 jt | 435,71% |
Total liabilitas | 356,00 rb | -80,72% |
Total ekuitas | 3,99 jt | — |
Saham yang beredar | 914,23 rb | — |
Harga terhadap nilai buku | 1,35 | — |
Tingkat pengembalian aset | -94,31% | — |
Tingkat pengembalian modal | -102,53% | — |
Arus Kas
Perubahan kas bersih
| (USD) | Jun 2024info | Perubahan Y/Y |
|---|---|---|
Laba bersih | -2,09 jt | -31,97% |
Kas dari operasi | -2,07 jt | -85,97% |
Kas dari investasi | — | — |
Kas dari pembiayaan | — | — |
Perubahan kas bersih | -2,07 jt | -85,97% |
Arus kas bebas | -1,27 jt | -22,46% |
Tentang
Titan Pharmaceuticals, Inc. is a biopharmaceutical company based in San Francisco, CA developing proprietary therapeutics primarily for the treatment of central nervous system disorders. In September 2018, Titan Pharmaceuticals underwent an IPO wherein it raised $9.5 million in gross proceeds. In the same month, it also posted approximately $1.7 million in revenue, in large part drawn from its licensing for its European intellectual property rights for Probuphine to the Italian pharmaceutical company Molteni - a leading European opioid manufacturer and also a subsidiary of the German Pharmaceutical juggernaut Merck Group.
Titan's principal asset is Probuphine, a slow-release implant formulation of buprenorphine for the treatment of opioid addiction or chronic pain. FDA Approval was granted on 26 May 2016. It was licensed to Braeburn Pharmaceuticals for marketing and commercialization. Wikipedia
Didirikan
1991
Kantor pusat
Situs
Karyawan
4
